NCT02735031View on ClinicalTrials.gov

Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

February 21, 2017

Primary Completion Date

March 28, 2018

Study Completion Date

April 9, 2018

Conditions

Diabetes Mellitus, Type 1Hypoglycemia

Interventions

DRUG

Exenatide

6 weeks treatment with exenatide on top of insulin treatment

DRUG

Placebo

6 weeks treatment with placebo on top of insulin treatment

Trial Locations (1)

Unknown

Radboud university medical centre, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

Radboud University Medical Center

OTHER